Form 4: Aethlon Medical Director Nicolas Gikakis Receives RSUs
Statement of Changes in Beneficial Ownership
Director Nicolas Gikakis acquired 21,815 restricted stock units in Aethlon Medical Inc. as part of a compensation grant.
Summary
- Director Nicolas Gikakis was granted 21,815 restricted stock units (RSUs) of Aethlon Medical Inc. (AEMD).
- The grant was valued at $2.29 per share.
- The RSUs are subject to a vesting schedule spanning from June 30, 2026, through March 31, 2027.
- Following this transaction, the director's total direct beneficial ownership increased to 22,844 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation rather than a signal of operational performance.
Positives
- Alignment of director interests with shareholders through equity-based compensation.
- Demonstrates commitment to the company through continued service requirements for vesting.
Negatives
- Dilutive impact on existing shareholders, though minor in scale.
Risks
- Vesting is contingent upon the director's continued service with the company.
Future Outlook
The RSUs will vest in four equal quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026, and March 31, 2027, provided the director remains in service.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard corporate governance practice in the biotechnology sector to ensure long-term alignment between board members and shareholders.
Comparison to Industry Standards
- The use of time-based RSU vesting is consistent with standard compensation practices for small-cap biotech companies.
- The grant size is relatively modest and typical for non-executive director compensation packages.
Stakeholder Impact
- Minor dilution for existing shareholders upon the eventual vesting and issuance of shares.
Next Steps
- Vesting of the first tranche of RSUs on June 30, 2026.
Key Dates
| Date | Description |
|---|---|
| 04/17/2026 | Date of the RSU grant transaction. |
| 04/21/2026 | Date the Form 4 was filed with the SEC. |
| 06/30/2026 | First quarterly vesting date for the RSUs. |
| 03/31/2027 | Final quarterly vesting date for the RSUs. |
Keywords
Aethlon Medical, AEMD, Form 4, Insider Trading, Restricted Stock Units, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.